drugset / Trial / NCT04398147
Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
Phase 1/2
Unknown
696 enrolled
CanSino Biologics Inc.
Beijing Institute of Biotechnology · collabCanadian Center for Vaccinology · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study is a phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to \<55 and 65 to \<85 years of age，with the randomized, observer-blind, dose-escalation design
Timeline
- Start
- 2020-08-01
- Primary completion
- 2021-12-20
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad5-nCoV | Vaccine | 5e+10 unknown | Intramuscular |
| Subject | Ad5-nCoV | Vaccine | 1e+11 unknown | Intramuscular |